Product Information
TADALAFIL 2.5 MG TABLET is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.1127 per EA under NDC 75834024701. Its NADAC has been published 138 times since Feb 14, 2024.
FDA first approved this application on Oct 23, 2020. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Nivagen Pharmaceuticals Inc.NDC
75834024701
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TADALAFILApproval Type
Generic (ANDA)
FDA Application
ANDA211298FDA Approved
10/23/2020
TE Code
AB1
On Market Since
11/2/2020
Pharmacological Classes
Price Statistics
The NADAC for TADALAFIL 2.5 MG TABLET has been published 138 times since Feb 14, 2024, and over the history we have for it it has declined 33.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1127 per EA |
|---|---|
| All-time high | $0.2190 (Mar 13, 2024) |
| All-time low | $0.0828 (Jul 17, 2024) |
| 52-week high | $0.1262 |
| 52-week low | $0.1127 |
| Median price | $0.1225 |
| Average price | $0.1239 |
| Largest weekly change | +53.6% (Aug 21, 2024) |
| Weeks tracked | 138 |
| Tracking since | Feb 14, 2024 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Nivagen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tadalafil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 5 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TADALAFIL 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TADALAFIL 2.5 MG TABLET, manufactured by Nivagen Pharmaceuticals Inc., is $0.1127 per EA (NDC 75834024701), effective Sep 30, 2026.
How has the price of TADALAFIL 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for TADALAFIL 2.5 MG TABLET has declined 33.4%. It has been tracked across 138 weekly CMS publications since Feb 14, 2024.
What are the highest and lowest recorded NADAC prices for TADALAFIL 2.5 MG TABLET?
Since Feb 14, 2024, the NADAC for TADALAFIL 2.5 MG TABLET has ranged from a low of $0.0828 (Jul 17, 2024) to a high of $0.2190 (Mar 13, 2024), with a median of $0.1225 per EA.
Are there cheaper alternatives to TADALAFIL 2.5 MG TABLET?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TADALAFIL 2.5 MG TABLET, is $0.1124 per EA — about 0% below TADALAFIL 2.5 MG TABLET.
Who manufactures TADALAFIL 2.5 MG TABLET?
TADALAFIL 2.5 MG TABLET (NDC 75834024701) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.